Daraprim Drug Pricing Suit Against Shkreli And Vyera May Signal Future FTC Actions

In joint complaint, the FTC and New York Attorney General allege scheme to block generic Daraprim and maintain exorbitant list price; they cite hundreds of emails the incarcerated Shkreli has exchanged with co-defendant in last six months.

NEW YORK - JUNE 29, 2017 - Martin Shkreli leaves federal court on June 29, 2017 in Brooklyn, New York.
FTC and New York Attorney General file antitrust suit againt former Turing Pharmaceuticals CEO Martin Shkreli

It has been over four years since Turing Pharmaceuticals AG and its founder Martin Shkreli raised the price of the antiparasitic drug Daraprim (pyrimethamine) by more than 4,000 percent, putting a spotlight on drug pricing. But the US Federal Trade Commission and New York Attorney General allege that since then they have engaged in an anticompetitive scheme to block generic competition and keep the price of the drug exorbitantly high.

On 27 January, the FTC and state of New York jointly filed a redacted complaint against [Vyera Pharmaceuticals LLC],...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Legal & IP

More from Pink Sheet